Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2014

Open Access 01-02-2014 | Research article

Patients’ preferences for osteoporosis drug treatment: a discrete-choice experiment

Authors: Mickaël Hiligsmann, Benedict G Dellaert, Carmen D Dirksen, Trudy van der Weijden, Stefan Goemaere, Jean-Yves Reginster, Verity Watson, Annelies Boonen

Published in: Arthritis Research & Therapy | Issue 1/2014

Login to get access

Abstract

Introduction

The patient’s perspective is becoming increasingly important in clinical and policy decisions. In this study, we aimed to evaluate the preferences of patients with, or at risk of, osteoporosis for medication attributes, and to establish how patients trade between these attributes.

Methods

A discrete choice experiment survey was designed and patients were asked to choose between two hypothetical unlabelled drug treatments (and an opt-out option) that vary in five attributes: efficacy in reducing the risk of fracture, type of potential common side-effects, mode and frequency of administration and out-of-pocket costs. An efficient experimental design was used to construct the treatment option choice sets and a mixed logit panel data model was used to estimate patients’ preferences and trade-offs between attributes.

Results

A total of 257 patients with, or at risk of, osteoporosis completed the experiment. As expected, patients preferred treatment with higher effectiveness and lower cost. They also preferred either an oral monthly tablet or 6-month subcutaneous injection above weekly oral tablets, 3-month subcutaneous, 3-month intravenous or yearly intravenous injections. Patients disliked being at risk of gastro-intestinal disorders more than being at risk of skin reactions and flu-like symptoms. There was significant variation in preferences across the sample for all attributes except subcutaneous injection.

Conclusions

This study revealed that osteoporotic patients preferred 6-month subcutaneous injection and oral monthly tablet, and disliked gastro-intestinal disorders. Moreover, patients were willing to pay a personal contribution or to trade treatment efficacy for better levels of other attributes. Preferences for treatment attributes varied across patients and this highlights the importance of clinical decision-making taking individual preferences into account to improve osteoporosis care.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J: Conjoint analysis applications in health – a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011, 14: 403-413. 10.1016/j.jval.2010.11.013.CrossRefPubMed Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J: Conjoint analysis applications in health – a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011, 14: 403-413. 10.1016/j.jval.2010.11.013.CrossRefPubMed
2.
go back to reference Brennan PF, Strombom I: Improving health care by understanding patient preferences: the role of computer technology. JAMIA. 1998, 5: 257-262.PubMedPubMedCentral Brennan PF, Strombom I: Improving health care by understanding patient preferences: the role of computer technology. JAMIA. 1998, 5: 257-262.PubMedPubMedCentral
3.
go back to reference Salzburg Global Seminar: Salzburg statement on shared decision making. BMJ. 2011, 342: d1745-CrossRef Salzburg Global Seminar: Salzburg statement on shared decision making. BMJ. 2011, 342: d1745-CrossRef
4.
go back to reference Murphy DR, Smolen LJ, Klein TM, Klein RW: The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC Musculoskelet Disord. 2012, 13: 213-10.1186/1471-2474-13-213.CrossRefPubMedPubMedCentral Murphy DR, Smolen LJ, Klein TM, Klein RW: The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC Musculoskelet Disord. 2012, 13: 213-10.1186/1471-2474-13-213.CrossRefPubMedPubMedCentral
5.
go back to reference de Bekker-Grob EW, Ryan M, Gerard K: Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012, 21: 145-172. 10.1002/hec.1697.CrossRefPubMed de Bekker-Grob EW, Ryan M, Gerard K: Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012, 21: 145-172. 10.1002/hec.1697.CrossRefPubMed
6.
go back to reference Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, Johnson FR: Conjoint analysis applications in health – how are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008. Patient. 2010, 3: 249-256. 10.2165/11539650-000000000-00000.CrossRefPubMed Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, Johnson FR: Conjoint analysis applications in health – how are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008. Patient. 2010, 3: 249-256. 10.2165/11539650-000000000-00000.CrossRefPubMed
8.
go back to reference Darba J, Restovic G, Kaskens L, Balbona MA, Carbonell A, Cavero P, Jordana M, Prieto C, Molina A, Padró I: Patient preferences for osteoporosis in Spain: a discrete choice experiment. Osteoporos Int. 2011, 22: 1947-1954. 10.1007/s00198-010-1382-3.CrossRefPubMed Darba J, Restovic G, Kaskens L, Balbona MA, Carbonell A, Cavero P, Jordana M, Prieto C, Molina A, Padró I: Patient preferences for osteoporosis in Spain: a discrete choice experiment. Osteoporos Int. 2011, 22: 1947-1954. 10.1007/s00198-010-1382-3.CrossRefPubMed
9.
go back to reference de Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Pols HA, Koes BW, Steyerberg EW: Patients’ preferences for osteoporosis drug treatment: a discrete choice experiment. Osteoporos Int. 2008, 19: 1029-1037. 10.1007/s00198-007-0535-5.CrossRefPubMedPubMedCentral de Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Pols HA, Koes BW, Steyerberg EW: Patients’ preferences for osteoporosis drug treatment: a discrete choice experiment. Osteoporos Int. 2008, 19: 1029-1037. 10.1007/s00198-007-0535-5.CrossRefPubMedPubMedCentral
11.
go back to reference Cramer JA, Gold DT, Silverman SL, Lewiecki EM: A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007, 18: 1023-1031. 10.1007/s00198-006-0322-8.CrossRefPubMed Cramer JA, Gold DT, Silverman SL, Lewiecki EM: A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007, 18: 1023-1031. 10.1007/s00198-006-0322-8.CrossRefPubMed
12.
go back to reference Hiligsmann M, van Durme C, Geusens P, Dellaert BG, Dirksen CD, van der Weijden T, Reginster JY, Boonen A: Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Prefer Adherence. 2013, 7: 133-139.CrossRefPubMedPubMedCentral Hiligsmann M, van Durme C, Geusens P, Dellaert BG, Dirksen CD, van der Weijden T, Reginster JY, Boonen A: Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Prefer Adherence. 2013, 7: 133-139.CrossRefPubMedPubMedCentral
13.
go back to reference Lancsar E, Louviere J: Conducting discrete choice experiments to inform healthcare decision making: a user’s guide. Pharmacoeconomics. 2008, 26: 661-677. 10.2165/00019053-200826080-00004.CrossRefPubMed Lancsar E, Louviere J: Conducting discrete choice experiments to inform healthcare decision making: a user’s guide. Pharmacoeconomics. 2008, 26: 661-677. 10.2165/00019053-200826080-00004.CrossRefPubMed
14.
go back to reference Coast J, Al-Janabi H, Sutton EJ, Horrocks SA, Vosper AJ, Swancutt DR, Flynn TN: Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations. Health Econ. 2012, 21: 730-741. 10.1002/hec.1739.CrossRefPubMed Coast J, Al-Janabi H, Sutton EJ, Horrocks SA, Vosper AJ, Swancutt DR, Flynn TN: Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations. Health Econ. 2012, 21: 730-741. 10.1002/hec.1739.CrossRefPubMed
15.
go back to reference Ryan M, Gerard K, Amaya-Amaya M: Using Discrete Choice Experiments to Value Health and Health Care. 2008, Dordrecht: SpringerCrossRef Ryan M, Gerard K, Amaya-Amaya M: Using Discrete Choice Experiments to Value Health and Health Care. 2008, Dordrecht: SpringerCrossRef
16.
go back to reference Rizzoli R, Reginster JY, Boonen S, Bréart G, Diez-Perez A, Felsenberg D, Kaufman JM, Kanis JA, Cooper C: Adverse reactions and drug–drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011, 89: 91-104. 10.1007/s00223-011-9499-8.CrossRefPubMedPubMedCentral Rizzoli R, Reginster JY, Boonen S, Bréart G, Diez-Perez A, Felsenberg D, Kaufman JM, Kanis JA, Cooper C: Adverse reactions and drug–drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011, 89: 91-104. 10.1007/s00223-011-9499-8.CrossRefPubMedPubMedCentral
18.
go back to reference Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA, Bresnahan BW, Kanninen B, Bridges JF: Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013, 16: 3-13. 10.1016/j.jval.2012.08.2223.CrossRefPubMed Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA, Bresnahan BW, Kanninen B, Bridges JF: Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013, 16: 3-13. 10.1016/j.jval.2012.08.2223.CrossRefPubMed
20.
go back to reference Kristoffersen DT, Helgeland J, Clench-Aas J, Laake P, Veierod MB: Comparing hospital mortality – how to count does matter for patients hospitalized for acute myocardial infarction (AMI), stroke and hip fracture. BMC Health Serv Res. 2012, 12: 364-10.1186/1472-6963-12-364.CrossRefPubMedPubMedCentral Kristoffersen DT, Helgeland J, Clench-Aas J, Laake P, Veierod MB: Comparing hospital mortality – how to count does matter for patients hospitalized for acute myocardial infarction (AMI), stroke and hip fracture. BMC Health Serv Res. 2012, 12: 364-10.1186/1472-6963-12-364.CrossRefPubMedPubMedCentral
22.
go back to reference Hensher D, Rose J, Greene W: Applied Choice Analysis: A Primer. 2007, Cambridge, UK: Cambridge University Press Hensher D, Rose J, Greene W: Applied Choice Analysis: A Primer. 2007, Cambridge, UK: Cambridge University Press
23.
go back to reference Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL: Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009, 122: S3-S13.CrossRefPubMed Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL: Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009, 122: S3-S13.CrossRefPubMed
24.
go back to reference Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY: The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health. 2012, 15: 604-612. 10.1016/j.jval.2012.02.001.CrossRefPubMed Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY: The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health. 2012, 15: 604-612. 10.1016/j.jval.2012.02.001.CrossRefPubMed
25.
go back to reference Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S: Treatment of Osteoporosis in clinical Practice (TOP) Study Group. Osteoporos Int. 2006, 17: 914-921. 10.1007/s00198-006-0073-6.CrossRefPubMed Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S: Treatment of Osteoporosis in clinical Practice (TOP) Study Group. Osteoporos Int. 2006, 17: 914-921. 10.1007/s00198-006-0073-6.CrossRefPubMed
26.
go back to reference Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009, 361: 756-765. 10.1056/NEJMoa0809493.CrossRefPubMed Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009, 361: 756-765. 10.1056/NEJMoa0809493.CrossRefPubMed
27.
go back to reference Mulley AG, Trimble C, Elwyn G: Stop the silent misdiagnosis: patients’ preferences matter. BMJ. 2012, 345: e6572-10.1136/bmj.e6572.CrossRefPubMed Mulley AG, Trimble C, Elwyn G: Stop the silent misdiagnosis: patients’ preferences matter. BMJ. 2012, 345: e6572-10.1136/bmj.e6572.CrossRefPubMed
28.
go back to reference Hiligsmann M, Kanis JA, Compston J, Cooper C, Flamion B, Bergmann P, Body JJ, Boonen S, Bruyere O, Devogelaer JP, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY: Health technology assessment in osteoporosis. Calcif Tissue Int. 2013, 93: 1-14. 10.1007/s00223-013-9724-8.CrossRefPubMedPubMedCentral Hiligsmann M, Kanis JA, Compston J, Cooper C, Flamion B, Bergmann P, Body JJ, Boonen S, Bruyere O, Devogelaer JP, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY: Health technology assessment in osteoporosis. Calcif Tissue Int. 2013, 93: 1-14. 10.1007/s00223-013-9724-8.CrossRefPubMedPubMedCentral
29.
go back to reference Montori VM, Shah ND, Pencille LJ, Branda ME, Van Houten HK, Swiglo BA, Kesman RL, Tulledge-Scheitel SM, Jaeger TM, Johnson RE, Bartel GA, Melton LJ, Wermers RA: Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med. 2011, 124: 549-556. 10.1016/j.amjmed.2011.01.013.CrossRefPubMed Montori VM, Shah ND, Pencille LJ, Branda ME, Van Houten HK, Swiglo BA, Kesman RL, Tulledge-Scheitel SM, Jaeger TM, Johnson RE, Bartel GA, Melton LJ, Wermers RA: Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med. 2011, 124: 549-556. 10.1016/j.amjmed.2011.01.013.CrossRefPubMed
30.
go back to reference Silverman S, Calderon A, Kaw K, Childers TB, Stafford BA, Brynildsen W, Focil A, Koenig M, Gold DT: Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis. Osteoporos Int. 2013, 7: 2067-2077.CrossRef Silverman S, Calderon A, Kaw K, Childers TB, Stafford BA, Brynildsen W, Focil A, Koenig M, Gold DT: Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis. Osteoporos Int. 2013, 7: 2067-2077.CrossRef
Metadata
Title
Patients’ preferences for osteoporosis drug treatment: a discrete-choice experiment
Authors
Mickaël Hiligsmann
Benedict G Dellaert
Carmen D Dirksen
Trudy van der Weijden
Stefan Goemaere
Jean-Yves Reginster
Verity Watson
Annelies Boonen
Publication date
01-02-2014
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2014
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4465

Other articles of this Issue 1/2014

Arthritis Research & Therapy 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.